Navigation Links
Sinovac Initiates Clinical Trials for Inactivated Hepatitis A Vaccine in Ukraine
Date:9/15/2008

BEIJING, Sept. 15 /Xinhua-PRNewswire/ -- Sinovac Biotech Ltd. (Amex: SVA), a leading provider of vaccines in China, today announced the initiation of clinical trials in Ukraine for its inactivated hepatitis A vaccine, Healive, in September, 2008. The trials are being conducted by Biolik Biopharmaceutical Company, a vaccine manufacturer located in Kharkov, Ukraine to seek regulatory approval in the Country. Biolik will also market and distribute Healive in Ukraine, which has an estimated market opportunity of up to $10 million.

The clinical trials are expected to enroll approximately 300 adults and 200 children with dosing and follow-up occurring over a six month period. The Companies anticipate that it will take approximately nine to twelve months to complete the trial and receive regulatory approval.

Mr. Weidong Yin, Chairman, President and CEO, commented, "As a developer of world-class vaccines, our strategy has been to provide high quality vaccines to people around the world. Sinovac is continuing to pursue strategic distribution partnerships that enable us to enter attractive markets outside of China by leveraging our GMP-certified manufacturing capabilities, which are capable of providing low cost, highly scalable production. We look forward to seeing the Ukrainian market contribute to our sales growth."

About Biolik

"Biolik" is well known in Ukraine and ex-USSR as the manufacturer of many immunobiological and medicinal products. Its products are delivered to all regions of Ukraine, Russia and countries of the Commonwealth of Independent States. Biolik constantly focuses on the modernization of manufacturing and improvement of technological schemes. Industrial shops and sites that meet international standards are commissioned annually. Today, Biolik is the only enterprise in Ukraine that manufactures vaccines for prophylaxis of diphtheria, tetanus and pertussis. Additional information about Biolik is available on its website, http://www.biolik.com.ua .

About Sinovac

Sinovac Biotech Ltd. is a China-based biopharmaceutical company that focuses on the research, development, manufacture and commercialization of vaccines that protect against human infectious diseases. Sinovac's commercialized vaccines include Healive(R) (hepatitis A), Bilive(R) (combined hepatitis A and B), Anflu(R) (influenza) and Panflu(TM) (H5N1). Sinovac is currently developing Universal Pandemic Influenza vaccine and Japanese encephalitis vaccine. Additional information about Sinovac is available on its website, http://www.sinovac.com . To be added to our distribution list, please email: info@sinovac.com.

Safe Harbor Statement

This announcement contains forward-looking statements. These statements are made under the "safe harbor" provisions of the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by words or phrases such as "will," "expects," "anticipates," "future," "intends," "plans," "believes," "estimates" and similar statements. Among other things, the business outlook and quotations from management in this press release contain forward-looking statements. Statements that are not historical facts, including statements about Sinovac's beliefs and expectations, are forward-looking statements. Forward-looking statements involve inherent risks and uncertainties. A number of important factors could cause actual results to differ materially from those contained in any forward- looking statement. Sinovac does not undertake any obligation to update any forward-looking statement, except as required under applicable law.

For more information, please contact:

Helen G. Yang

Sinovac Biotech Ltd.

Tel: +86-10-8289-0088 x871

Fax: +86-10-6296-6910

Email: info@sinovac.com

Investors/Media:

Stephanie Carrington / Janine McCargo

The Ruth Group

Tel: +1-646-536-7017/7033

Email: scarrington@theruthgroup.com / jmccargo@theruthgroup.com


'/>"/>
SOURCE Sinovac Biotech Ltd.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Sinovac Launches Seasonal Influenza Vaccine Anflu(R) for 2008-2009 Flu Season
2. Sinovac Adjourns Annual General Meeting
3. Sinovac to Present at the Susquehanna Financial Groups Second Annual Beijing Management Summit Conference
4. Sinovac Reports Record Second Quarter 2008 Unaudited Financial Results
5. Sinovac Biotech Ltd. Schedules 2007 Annual Meeting of Shareholders
6. Sinovac Receives Healive(R) and Bilive(R) Purchase Orders from Provincial CDCs for Earthquake Disaster Areas
7. Sinovac Receives RMB 20 Million Purchase Order for Healive from Chinas Ministry of Health to Vaccinate Earthquake Victims
8. Sinovac to Present at the Brean Murray, Carret & Co. All-Cap All-China Conference and the Roth China Discovery Tour 2008
9. Sinovac Biotech Holds Annual General Meeting
10. Sinovac Reports Fourth Quarter and Full Year 2007 Financial Results
11. Sinovac to Host Conference Call to Report Fourth Quarter and Full Year 2007 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2017)... (PRWEB) , ... June 26, 2017 , ... Third Wave ... role of Sales Director, focused on leading new business development and ensuring quality customer ... of experience in the food ingredient industry in technical, marketing and sales roles. “Brett’s ...
(Date:6/23/2017)... (PRWEB) , ... June 23, 2017 , ... Ken Hanson, ... president of Physik Instrumente USA, have been selected as this year’s recipients of two ... The two have been invited along with other honorees to accept their awards at ...
(Date:6/22/2017)... ... June 21, 2017 , ... Building on the success of the inaugural RAADfest ... the very latest developments in radical life extension. RAADfest combines cutting edge science presented ... empowerment of personal development, making it the largest most comprehensive and inclusive super longevity ...
(Date:6/22/2017)... Linda, Ca (PRWEB) , ... June 22, 2017 , ... ... worldwide. It took 20 years until the first data on cross-contamination of human cell ... lines has been an increasing issue in cell culture labs and is associated with ...
Breaking Biology Technology:
(Date:4/5/2017)... 2017 KEY FINDINGS The global ... a CAGR of 25.76% during the forecast period of ... factor for the growth of the stem cell market. ... MARKET INSIGHTS The global stem cell market is ... geography. The stem cell market of the product is ...
(Date:4/3/2017)... 3, 2017  Data captured by IsoCode, ... detected a statistically significant association between the ... treatment and objective response of cancer patients ... predict whether cancer patients will respond to ... well as to improve both pre-infusion potency testing ...
(Date:3/30/2017)... The research team of The Hong Kong Polytechnic University ... adopting ground breaking 3D fingerprint minutiae recovery and matching technology, pushing ... for use in identification, crime investigation, immigration control, security of access ... ... A research team led by Dr Ajay ...
Breaking Biology News(10 mins):